Business Context and Reporting Period
Company: Inovio Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2026
Event: Entry into a Material Definitive Agreement for a public offering of common stock and warrants.
Key Financial Metrics and Offering Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Shares Offered: 12,500,000 shares of Common Stock.
- Warrants Issued:
- Series A Warrants: 12,500,000 (1-year term, immediately exercisable).
- Series B Warrants: 12,500,000 (5-year term, immediately exercisable).
- Exercise Price: $1.40 per share for Common Stock and Warrants ($1.399 for Pre-Funded Warrants).
- Public Offering Price: $1.40 per share (combined stock and warrants).
- Expected Net Proceeds: Approximately $16 million (excluding underwriting discounts, commissions, and expenses; assumes no exercise of over-allotment option).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,875,000 additional shares and corresponding warrants.
- Expected Closing Date: On or about April 6, 2026.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures. These operational metrics are not included in this specific 8-K report.
Material Changes Versus Prior Period
The filing does not present comparative financial data or operational changes versus a prior period. The material change reported is the execution of the underwriting agreement to raise capital, which will increase the company's cash position upon closing and increase the number of outstanding shares and warrants.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: The company issued press releases on April 1 and April 2, 2026, announcing the launch and pricing of the offering.
- Forward-Looking Statements: The report contains statements regarding expected net proceeds and closing dates, which are subject to risks and uncertainties.
- Risks: Investors are directed to the Annual Report on Form 10-K for the year ended December 31, 2025, for a detailed description of business risks. The offering is subject to customary closing conditions.
- Warrant Terms: Warrants include a 4.99% beneficial ownership limitation (electable up to 9.99% or adjustable up to 19.99% with notice). In certain fundamental transactions, holders may elect to have warrants purchased for fair market value using the Black-Scholes method.
Important Facts for Investor Verification
- Verify the actual closing date and final net proceeds once the transaction settles (expected April 6, 2026).
- Confirm whether the underwriters exercise the 30-day over-allotment option for an additional 1,875,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) and Warrant forms (Exhibits 4.1, 4.2, 4.3) for specific covenants and redemption rights.
- Check the company's most recent Form 10-K (year ended Dec 31, 2025) for current liquidity status and cash burn rate to assess the impact of the $16 million raise.
- Monitor the stock price relative to the $1.40 exercise price to evaluate the immediate dilution and warrant value.